PhD student, MD
Debbie Madsen
Department of Oncology, Odense University Hospital
| Projekt styring | ||
| Projekt status | Open | |
| Data indsamlingsdatoer | ||
| Start | 01.01.2026 | |
| Slut | 31.12.2027 | |
ICiDia - The clinical impact of diabetes on immune checkpoint inhibitor treatment in cancer patients
Short summary
The ICiDia Study investigates how diabetes influences quality of life in cancer patients treated with ICI. A national prospective cohort of 1,000 patients will be established to examine the impact of both pre-existing and treatment-induced diabetes on quality of life. Data are collected before, during, and after treatment to evaluate longitudinal changes in quality of life and assess the occurrence of immune-related diabetes.
Rationale
The aims of the ICiDia Study are to: 1. Compare longitudinal changes in HRQoL between patients with type 2 diabetes and non-diabetic patients during ICI therapy. 2. Estimate the incidence and clinical characteristics of immune-related diabetes in a nationwide, real-world cohort. 3. Assess baseline HRQoL differences between patients with and without pre-existing diabetes, including subtype comparisons (type 1 diabetes and type 2 diabetes). 4. Evaluate HRQoL trajectories in patients with type 1 diabetes and immune-related diabetes during treatment. 5. Explore survival outcomes by diabetes status and subtype over 12 months.
Description of the cohort
The cohort will include 1,000 patients with solid malignant tumours scheduled to receive ICI therapy at the Departments of Oncology at Odense, Aarhus, Aalborg, and Herlev University Hospitals. Patients are recruited from outpatient oncology clinics and followed for 12 months after treatment initiation.
Data and biological material
Questionnaire data and relevant clinical information from medical records will be collected and stored securely using OPEN REDCap and institutional data storage solutions.
Collaborating researchers and departments
Department of Oncology, Aarhus Hospital, Skejby Department of Oncology, Aalborg Hospital Department of Oncology, Herlev Hospital